Pozelimab
R3918-PLE-1878
Phase 3 small_molecule completed
Quick answer
Pozelimab for CD55-deficient Protein-losing Enteropathy is a Phase 3 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- CD55-deficient Protein-losing Enteropathy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed